Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China.

Pharmacogenomics and Personalized Medicine Pub Date : 2021-12-17 eCollection Date: 2021-01-01 DOI:10.2147/PGPM.S327313

Yuliang Wang, Linna Peng, Hongyan Lu, Zhanhao Zhang, Shishi Xing, Dandan Li, Chunjuan He, Tianbo Jin, Li Wang

{"title":"Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China.","authors":"Yuliang Wang, Linna Peng, Hongyan Lu, Zhanhao Zhang, Shishi Xing, Dandan Li, Chunjuan He, Tianbo Jin, Li Wang","doi":"10.2147/PGPM.S327313","DOIUrl":null,"url":null,"abstract":"Background: We aimed to enrich the pharmacogenomic information of a Blang population (BP) from Yunnan Province in China.Methods: We genotyped 55 very important pharmacogene (VIP) variants from the PharmGKB database and compared their genotype distribution (GD) in a BP with that of 26 populations by the χ 2 test. The minor allele frequency (MAF) distribution of seven significantly different single-nucleotide polymorphisms (SNPs) was conducted to compare the difference between the BP and 26 other populations.Results: Compared with the GD of 55 loci in the BP, among 26 studied populations, GWD, YRI, GIH, ESN, MSL, TSI, PJL, ACB, FIN and IBS were the top-10 populations, which showed a significantly different GD >35 loci. CHB, JPT, CDX, CHS, and KHV populations had a significantly different GD <20 loci. A GD difference of 27-34 loci was found between the BP and 11 populations (LWK, CEU, ITU, STU, PUR, CLM, GBR, ASW, BEB, MXL and PEL). The GD of five loci (rs750155 (SULT1A1), rs4291 (ACE), rs1051298 (SLC19A1), rs1131596 (SLC19A1) and rs1051296 (SLC19A1)) were the most significantly different in the BP as compared with that of the other 26 populations. The genotype frequency of rs1800764 (ACE) and rs1065852 (CYP2D6) was different in all populations except for PEL and LWK, respectively. MAFs of rs1065852 (CYP2D6) and rs750155 (SULT1A1) showed the largest fluctuation between the BP and SAS, EUR, AFR and AMR populations.Conclusion: Our data can provide theoretical guidance for safe and efficacious personalized drug use in the Blang population.","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1647-1660"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/25/pgpm-14-1647.PMC8691194.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics and Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S327313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background: We aimed to enrich the pharmacogenomic information of a Blang population (BP) from Yunnan Province in China.

Methods: We genotyped 55 very important pharmacogene (VIP) variants from the PharmGKB database and compared their genotype distribution (GD) in a BP with that of 26 populations by the χ ² test. The minor allele frequency (MAF) distribution of seven significantly different single-nucleotide polymorphisms (SNPs) was conducted to compare the difference between the BP and 26 other populations.

Results: Compared with the GD of 55 loci in the BP, among 26 studied populations, GWD, YRI, GIH, ESN, MSL, TSI, PJL, ACB, FIN and IBS were the top-10 populations, which showed a significantly different GD >35 loci. CHB, JPT, CDX, CHS, and KHV populations had a significantly different GD <20 loci. A GD difference of 27-34 loci was found between the BP and 11 populations (LWK, CEU, ITU, STU, PUR, CLM, GBR, ASW, BEB, MXL and PEL). The GD of five loci (rs750155 (SULT1A1), rs4291 (ACE), rs1051298 (SLC19A1), rs1131596 (SLC19A1) and rs1051296 (SLC19A1)) were the most significantly different in the BP as compared with that of the other 26 populations. The genotype frequency of rs1800764 (ACE) and rs1065852 (CYP2D6) was different in all populations except for PEL and LWK, respectively. MAFs of rs1065852 (CYP2D6) and rs750155 (SULT1A1) showed the largest fluctuation between the BP and SAS, EUR, AFR and AMR populations.

Conclusion: Our data can provide theoretical guidance for safe and efficacious personalized drug use in the Blang population.

Abstract Image

查看原文本刊更多论文

云南布朗族重要药物基因变异的遗传多态性

背景:本研究旨在丰富云南省一个布朗族群体(BP)的药物基因组学信息。方法:从PharmGKB数据库中对55个非常重要的药物基因(VIP)变异进行基因分型，并通过χ 2检验比较其在BP中的基因型分布(GD)与26个人群的基因型分布(GD)。对7个差异显著的单核苷酸多态性(snp)进行了次要等位基因频率(MAF)分布，比较了BP与其他26个群体的差异。结果:与BP中55个位点的GD值比较，在26个研究群体中，GWD、YRI、GIH、ESN、MSL、TSI、PJL、ACB、FIN和IBS居前10位，GD值>35个位点差异显著。CHB、JPT、CDX、CHS和KHV群体GD差异显著(SULT1A1)，其中rs4291 (ACE)、rs1051298 (SLC19A1)、rs1131596 (SLC19A1)和rs1051296 (SLC19A1)的BP与其他26个群体差异最显著。rs1800764 (ACE)和rs1065852 (CYP2D6)基因型频率在除PEL和LWK外的所有人群中均存在差异。rs1065852 (CYP2D6)和rs750155 (SULT1A1)的maf在BP与SAS、EUR、AFR和AMR群体之间波动最大。结论:本研究结果可为布朗族人群安全有效的个体化用药提供理论指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics and Personalized Medicine

自引率

0.00%

发文量